5-Amino-1MQ: An NNMT Inhibitor for Adipose Metabolism and Fat Loss Research

This content is provided by Superpower Health for educational and informational purposes only. 5-Amino-1MQ is a preclinical research compound not approved by the FDA for any indication. It is not available through Superpower, not available by prescription, and has not completed any published human clinical trials. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Every well-studied drug target in metabolic medicine has a molecular villain. For obesity and insulin resistance, nicotinamide N-methyltransferase (NNMT) has emerged as a compelling one. The enzyme is overexpressed in the adipose tissue of people with obesity. It consumes methyl groups, depletes the cellular substrate needed for energy regulation, and appears to actively suppress the metabolic activity of fat cells. 5-Amino-1MQ is a small molecule designed to inhibit it. It is not FDA-approved and has not been tested in published human clinical trials.

Here is how 5-Amino-1MQ works, what the preclinical evidence shows, and what researchers and clinicians actually know — and do not know — about this compound.

Key Takeaways

• Regulatory Status: Not FDA-approved for any indication. Preclinical research compound with no published human trials as of April 2026.
• Research Stage: Preclinical (animal studies only); no completed or registered Phase 1, 2, or 3 human trials published as of April 2026.
• Availability: Not available through Superpower. Distributed through gray-market research chemical vendors; not available by prescription from any licensed compounding pharmacy with established clinical protocols.
• Prescribing information: No FDA-approved label exists. For context, see the ClinicalTrials.gov registry for NNMT inhibitor studies.
• How it works: Inhibits NNMT, an enzyme that depletes S-adenosylmethionine (SAM) in adipose tissue, thereby shifting cellular metabolism toward fat oxidation and energy expenditure.
• What preclinical studies show: In diet-induced obese mice, 5-Amino-1MQ reversed obesity and improved glucose tolerance; no published human data exists to confirm these effects translate to humans.

Because no human trials have been published, the evidence base for 5-Amino-1MQ consists entirely of animal studies and in vitro work. Preclinical findings in mice frequently do not replicate in humans, particularly in metabolic research, where multiple prior "promising" targets have failed at the human trial stage. Any use of this compound outside a supervised research setting carries unknown risks.

What Is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a membrane-permeable, selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It is not a peptide. It is a methylquinolinium salt — a synthetic organic compound developed through medicinal chemistry optimization of NNMT-inhibitor scaffolds. It has no FDA-approved indication and is not the subject of any registered completed human trial as of April 2026. The compound exists in the research literature through a series of publications from the University of Texas Health Science Center, where it was developed and characterized starting around 2017.

How 5-Amino-1MQ Works

NNMT and the SAM depletion mechanism

NNMT is an enzyme that transfers a methyl group from S-adenosylmethionine (SAM) onto nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine (SAH). SAM is the cell's primary methyl donor — the same molecule required for methylation of DNA, histones, and multiple metabolic intermediates. When NNMT is highly active, it depletes SAM, reducing the cell's methylation capacity. In adipose tissue, Roberti, Fernández, and Fraga, writing in Molecular Metabolism in 2021, established that NNMT sits at the crossroads of cellular metabolism and epigenetic regulation: its activity directly affects the methyl economy that governs gene expression and energy metabolism in fat cells. By inhibiting NNMT, 5-Amino-1MQ preserves SAM, shifts the methylation balance back toward anabolic-to-catabolic gene regulation, and — in animal models — alters fat cell energy expenditure.

NNMT overexpression in obesity

NNMT is not uniformly expressed. In lean individuals its activity in adipose tissue is relatively low. In obese individuals, NNMT expression in white adipose tissue and liver rises substantially. A 2015 clinical study by Kannt, Pfenninger, and colleagues published in Diabetologia measured NNMT mRNA in white adipose tissue and plasma 1-methylnicotinamide (MNA) concentrations across 314 participants (199 surgical patients, 60 enrolled in an exercise intervention, 55 undergoing bariatric surgery) and found that plasma MNA correlated significantly with WAT NNMT expression in patients with type 2 diabetes and that plasma MNA was inversely correlated with insulin sensitivity; interventions that improved insulin sensitivity (exercise and bariatric surgery) produced significant reductions in adipose NNMT expression — providing the key human data point linking NNMT activity to metabolic dysfunction. Rudolphi, Zapp, Kraus, and colleagues, writing in Endocrine Research in 2018, extended this observation in rodents: body weight itself predicted NNMT activity in adipose tissue, suggesting that obesity and NNMT upregulation track together in a graded fashion. A broader 2021 review by Liu, Deng, Zhu, and colleagues in BioMed Research International synthesized the literature on NNMT in obesity and type 2 diabetes, concluding that elevated NNMT activity is a consistent feature of both conditions across human and animal studies. The causal direction in humans remains unestablished; correlation does not confirm that reducing NNMT activity would reverse these metabolic changes. What the human data does establish is that the NNMT axis is biologically active in human obesity, which motivates the translational interest in NNMT inhibitors.

Human genetic data adds a further layer. Bañales-Luna, Figueroa-Vega, Marín-Aragón, and colleagues, publishing in Scientific Reports in 2020, reported associations between NNMT, FTO, and IRX3 genetic variants and both BMI and resting energy expenditure in a Mexican cohort — evidence that variation in the NNMT axis tracks with metabolic phenotype in humans, not only in mice. Crujeiras, Pissios, Moreno-Navarrete, and colleagues, writing in Molecular Nutrition and Food Research in 2018, identified an epigenetic signature in human adipose tissue linked to NNMT gene expression, reinforcing the idea that the methylation axis is a live variable in human fat biology rather than a rodent-only phenomenon.

Mechanism of NNMT inhibition by 5-Amino-1MQ

A 2017 structure-activity relationship study by Neelakantan, Wang, Vance, and colleagues published in the Journal of Medicinal Chemistry, characterized the medicinal chemistry behind 5-Amino-1MQ and related quinolinium analogs. The study demonstrated that this chemotype achieves selective NNMT inhibition while remaining membrane-permeable — a critical property because NNMT operates intracellularly. Selectivity matters: SAM is used by dozens of methyltransferases, and a non-selective SAM-depleting agent would interfere broadly with methylation biology. The quinolinium scaffold of 5-Amino-1MQ is designed to bind the NNMT active site specifically, leaving other SAM-dependent enzymes largely unaffected in the concentrations studied.

Several preclinical studies help explain what happens downstream of that inhibition inside fat cells. Xu, Hou, Li, and colleagues, publishing in Bioengineered in 2022, examined the effect of NNMT on lipid accumulation in 3T3-L1 adipocytes using lentiviral RNAi knockdown (NNMT reduced to approximately 27% of control mRNA) and plasmid-driven overexpression, and found that NNMT knockdown significantly reduced lipid accumulation (1.000 ± 0.004 vs. 0.753 ± 0.008, p < 0.0001) and triglyceride content (146.6 vs. 73.2 mg/mg protein, p < 0.05), while NNMT overexpression produced the opposite effect (triglyceride content 117.2 vs. 229.0 mg/mg protein, p < 0.0001) — consistent with the hypothesis that inhibiting NNMT reduces the adipocyte's capacity to store fat. This is an in vitro cell-line study; translation to human adipose tissue is not established. Ehebauer, Ghavampour, and Kraus, writing in Life Sciences in 2020, showed that glucose availability dynamically regulates NNMT expression in adipocytes — linking the enzyme's activity to the nutrient environment of the cell. Jia, Wei, and Jiang, publishing in the Journal of Physiology and Biochemistry in 2022, observed that NNMT is induced dynamically during beige adipogenesis in a depot-specific manner, suggesting that NNMT activity is not merely a marker of dysfunctional fat but an active participant in determining adipose tissue identity. Roberti, Tejedor, and colleagues, in a 2023 Scientific Reports paper, further demonstrated that NNMT regulates the glucocorticoid signaling pathway during early adipogenesis — a mechanistic link between NNMT activity and the hormonal pathways that govern fat cell differentiation.

The NAD+ axis connection

NNMT's substrate, nicotinamide, is also a precursor in NAD+ biosynthesis. When NNMT methylates nicotinamide into 1-methylnicotinamide, it diverts nicotinamide away from the salvage pathway that replenishes NAD+. This creates a biological overlap with the NAD+ precursor landscape that includes nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Kwon and Park, writing in Adipocyte in 2024, reviewed the function of NAD+ metabolism specifically in white adipose tissue and confirmed that NAD+ availability in fat cells directly influences metabolic programming. Yamaguchi and Yoshino, writing in BioEssays in 2017, characterized adipose tissue NAD+ biology as central to the development of insulin resistance in obesity. Nielsen, Peics, Ma, and colleagues, publishing in Molecular Metabolism in 2018, demonstrated that NAMPT-mediated NAD+ biosynthesis is indispensable for adipose tissue plasticity and obesity development — underscoring that the NAD+ salvage pathway is not an incidental side note but a core determinant of fat cell function. The framing: NNMT inhibition conserves nicotinamide for NAD+ production while also restoring SAM-dependent methylation — a dual metabolic effect that NR or NMN supplementation alone would not reproduce, since those compounds add to the NAD+ pool without addressing the methylation drain.

What the Preclinical Research Shows

The Kraus 2014 landmark study

The foundational scientific rationale for NNMT as a metabolic target came from a 2014 study by Kraus, Yang, Kong, and colleagues published in Nature. The investigators used antisense oligonucleotides (ASO) to knock down NNMT expression specifically in white adipose tissue and liver of diet-induced obese C57BL/6 mice (n = 8 per group for primary analyses) over 8 weeks. The results were striking: NNMT-ASO-treated mice showed significantly reduced body weight gain compared to control-ASO animals on the same high-fat diet (p < 0.05), reduced fat mass as a percentage of body weight (p < 0.05), improved glucose tolerance with reduced area under the curve on intraperitoneal glucose tolerance testing (p < 0.05), decreased serum insulin (p < 0.05), and reduced hepatic triglycerides (p < 0.05). This study established the proof-of-concept that reducing NNMT activity in adipose tissue produces systemic metabolic benefits in mice. It is the core citation behind all downstream NNMT-inhibitor drug discovery, including 5-Amino-1MQ — but it used a genetic approach (ASO), not a small-molecule inhibitor, and it was conducted in rodents.

5-Amino-1MQ in diet-induced obese mice: the 2018 pivotal study

The pivotal 5-Amino-1MQ paper published in Biochemical Pharmacology in 2018 by Neelakantan, Vance, Wetzel, and colleagues translated the Kraus genetic approach into a pharmacological one. The investigators administered 5-Amino-1MQ to diet-induced obese C57BL/6 mice at 20 mg/kg three times daily subcutaneously over 11 days (n = 9 per group) and demonstrated that the compound reversed obesity: treated animals showed significantly reduced body weight (p < 0.05) and white adipose mass (p < 0.01) without changes in food intake, alongside lowered plasma total cholesterol (p < 0.05) and decreased adipocyte size (p < 0.0001), consistent with enhanced lipid oxidation rather than reduced lipid intake. No observable adverse effects were reported. This was the first demonstration that a selective small-molecule NNMT inhibitor could reproduce the metabolic benefits observed in the antisense knockdown model. The small cohort and short duration limit the strength of any translational inference, and the study was conducted in mice only; no human data were generated or presented.

5-Amino-1MQ combined with calorie restriction

Two subsequent studies examined 5-Amino-1MQ in combination with dietary intervention. Sampson, Dimet, Neelakantan, and colleagues, publishing in Scientific Reports in 2021, administered an NNMT inhibitor alongside a lean-diet substitution in diet-induced obese mice (n = 6–8 per group) and found that the combination significantly reduced body weight and fat mass (both p < 0.0001) and lowered liver lobe fat content (p = 0.0034), total liver weight (p = 0.0011), and both microvesicular (p = 0.0425) and macrovesicular (p = 0.0039) hepatic steatosis beyond either intervention alone. Dimet-Wiley, Wu, and colleagues, also publishing in Scientific Reports in 2022, found that NNMT inhibition combined with calorie restriction altered gut microbiome composition in diet-induced obese mice — suggesting systemic metabolic effects that extend beyond adipose tissue, though the clinical significance in humans is unknown.

Skeletal muscle and aging

A 2019 study by Neelakantan, Brightwell, Graber, and colleagues in Biochemical Pharmacology extended the same NNMT-inhibitor chemotype (referred to in the paper as "NNMTi," a quinolinium small molecule from the 5-Amino-1MQ family, dosed at 5 and 10 mg/kg) to a different tissue context: aged skeletal muscle in 24-month-old mice. The investigators found that NNMT inhibition elevated muscle stem cell proliferation and fusion — supporting nearly 2-fold greater cross-sectional area — and increased peak tibialis anterior torque by approximately 70% compared with controls, suggesting improved regenerative capacity of aged skeletal muscle. This opened a second research avenue alongside the adipose-tissue metabolic work — potential relevance to muscle aging and regeneration. As with the obesity data, these findings are in rodents only.

Pharmacokinetics: the only direct PK study

Awosemo, Neelakantan, and colleagues, publishing in the Journal of Pharmaceutical and Biomedical Analysis in 2021, developed and validated an LC-MS/MS assay to measure 5-amino-1-methylquinolinium concentrations in rat plasma and characterized the compound's oral bioavailability in rats. This is, as of April 2026, the only published pharmacokinetic study of 5-Amino-1MQ. The study was conducted in rats. Human pharmacokinetics — absorption, distribution, metabolism, elimination, half-life, and dose-exposure relationships — have not been published.

The broader NNMT inhibitor pipeline

5-Amino-1MQ is not the only NNMT inhibitor under investigation. Ruf, Rajagopal, Kadnur, and colleagues, publishing in Scientific Reports in 2022, described novel tricyclic small-molecule NNMT inhibitors designed for metabolic disorders, confirming that NNMT inhibition is an active pharmaceutical pipeline pursued by multiple academic and commercial groups — not solely a gray-market compound. A 2021 review by Kannt, Rajagopal, and Hallur in Molecules surveyed the full landscape of novel NNMT inhibitors across structural classes. Gao, Martin, and van Haren, writing in Drug Discovery Today in 2021, characterized NNMT as an emerging therapeutic target with expanding relevance across metabolic disorders. The most recent preclinical efficacy study, Babula, Bui, Stevenson, and colleagues, published in Diabetes, Obesity and Metabolism in 2024, confirmed that NNMT inhibition mitigates obesity-related metabolic dysfunction in preclinical models. Most recently, Sun, Zhu, and colleagues, writing in Frontiers in Pharmacology in 2024, reviewed NNMT as a novel therapeutic target for metabolic syndrome, noting the expanding body of mechanistic evidence and the continued absence of human trial data.

5-Amino-1MQ Compared to NAD+ Precursors (NR and NMN)

5-Amino-1MQ and NAD+ precursors (nicotinamide riboside and NMN) operate on adjacent but distinct parts of the same metabolic axis. Understanding the difference clarifies why they are not interchangeable.

NR and NMN supplement the NAD+ pool directly. They provide additional substrate for NAD+ synthesis, increasing cellular NAD+ levels. The metabolic rationale is that declining NAD+ with age impairs sirtuin activity, mitochondrial function, and energy regulation. Yoshino, Baur, and Imai, reviewing the biology in Cell Metabolism in 2018, characterized NAD+ intermediates NMN and NR and their therapeutic potential across aging and metabolic contexts. In humans, the evidence is more modest than the preclinical data suggested. A 12-week randomized, double-blind, placebo-controlled, parallel-group trial by Dollerup, Christensen, and colleagues published in the American Journal of Clinical Nutrition in 2018 tested nicotinamide riboside supplementation at 1,000 mg twice daily (2,000 mg/day total) in 40 obese, insulin-resistant men and concluded that while the dose appeared safe, NR did not improve insulin sensitivity, endogenous glucose production, or whole-body glucose disposal or oxidation compared with placebo. A 2023 review by Damgaard and Treebak in Science Advances summarized the human nicotinamide riboside literature and concluded that evidence for meaningful metabolic benefits in humans remains limited and inconsistent.

5-Amino-1MQ approaches the same axis differently. Rather than adding nicotinamide to increase NAD+, it blocks NNMT from consuming nicotinamide — preserving it for the NAD+ salvage pathway. Simultaneously, NNMT inhibition restores SAM levels, which NR and NMN supplementation does not address. The methylation angle is distinct: NNMT inhibition affects DNA and histone methylation patterns through SAM restoration, a mechanism with no parallel in the NR/NMN literature. In preclinical terms, the two approaches are complementary rather than competitive. Whether that distinction translates into superior human outcomes for 5-Amino-1MQ is unknown — no human trials have been conducted. Cross-mechanism comparisons between 5-Amino-1MQ animal data and human NR trial data are unreliable and should not be used to infer superiority.

Regulatory Status and Gray-Market Distribution

As of April 2026, 5-Amino-1MQ has no FDA-approved indication, no IND (Investigational New Drug) application on the public record, and no registered Phase 1, 2, or 3 clinical trial published in the peer-reviewed literature or listed as completed on ClinicalTrials.gov. It is a research compound that has moved from academic preclinical work into the gray market — sold by research chemical vendors as a "research use only" substance, often marketed alongside peptides and other investigational compounds in body-composition communities.

The compound's legal status in the United States as a gray-market research chemical means it is not a scheduled controlled substance, but it is also not approved for human use, not manufactured under pharmaceutical GMP standards when distributed commercially, and not subject to the pharmacovigilance requirements that govern FDA-regulated products. Purity, dosing accuracy, and absence of contamination in commercially distributed 5-Amino-1MQ have not been independently verified by a regulatory body. A 2025 review by Zhang, Zhu, Sun, and colleagues in Archives of Biochemistry and Biophysics highlighted the growing interest in NNMT as a therapeutic target for non-alcoholic fatty liver disease, underscoring that pharmaceutical-grade NNMT inhibitors remain in the research pipeline rather than available as regulated medicines.

Legitimate pharmaceutical NNMT inhibitor programs — distinct from the gray-market distribution of 5-Amino-1MQ — exist in academic and early-stage industry pipelines. Ruf, Rajagopal, Kadnur, and colleagues' 2022 work in Scientific Reports on tricyclic NNMT inhibitors is one example of parallel pharmaceutical chemistry research that aims to advance NNMT inhibition into a regulated clinical setting. Whether 5-Amino-1MQ specifically will enter formal human trials is unknown.

Side Effects and Safety: What the Evidence Does and Does Not Show

No published human safety data exists for 5-Amino-1MQ. The following reflects the available animal and in vitro literature only. It cannot be used to characterize the human safety profile of this compound.

In mouse studies, 5-Amino-1MQ was generally well tolerated at doses studied, with no gross toxicological findings reported in published papers. However, published rodent studies are not designed as formal toxicological evaluations; they are pharmacological efficacy studies that note the absence of obvious adverse effects without systematic organ-level safety assessment.

Theoretical concerns based on mechanism:

• NNMT inhibition raises SAM levels and alters cellular methylation. SAM is involved in dozens of methylation reactions throughout the body, including DNA methylation and histone modification. The downstream consequences of sustained SAM elevation — particularly in cell types outside the adipose tissue studied — are not characterized in the human context.
• 1-Methylnicotinamide, the product of NNMT activity, is itself a biologically active signaling molecule. Ström, Morales-Alamo, Ottosson, and colleagues, publishing in Scientific Reports in 2018, demonstrated that 1-methylnicotinamide produced in skeletal muscle coordinates energy metabolism as a signaling molecule. Sustained suppression of 1-methylnicotinamide production by NNMT inhibition may have effects on skeletal muscle energy regulation that have not been characterized.
• The gut microbiome is affected by NNMT inhibition in mice, as documented by Dimet-Wiley, Wu, and colleagues in 2022. Whether this represents a benefit, a risk, or a neutral consequence in humans is unknown.
• Long-term safety of NNMT inhibition — including effects on cancer risk given NNMT's expression in cancer cell biology — has not been studied.

No human pharmacokinetic, safety, or tolerability data for 5-Amino-1MQ has been published. Any use in humans is experimental.

Who Should Not Use 5-Amino-1MQ

Because 5-Amino-1MQ has not completed human clinical trials, formal contraindications derived from clinical data do not exist. The following reflects populations for whom use would be of particular concern given the compound's mechanism and the absence of human data:

• Any individual not enrolled in an IRB-approved clinical research study — in the absence of human safety data, use outside a supervised research context carries unknown risks
• Pregnant or breastfeeding individuals — no reproductive or developmental toxicology data exists
• Individuals with known or suspected malignancy — NNMT is expressed in multiple cancer types; the effect of pharmacological NNMT inhibition on tumor biology in humans is unknown
• Individuals taking medications that affect methylation pathways, folate metabolism, or SAM-dependent enzymes — no drug interaction studies have been conducted
• Individuals with hepatic or renal impairment — pharmacokinetics in compromised organ function are entirely uncharacterized

This is not an exhaustive list. The absence of human data means that the full range of contraindications is, by definition, unknown.

Approval Status and What Comes Next

As of April 2026, 5-Amino-1MQ has not entered the FDA regulatory pathway. No IND application has been announced publicly, no Phase 1 trial has been registered on ClinicalTrials.gov, and the compound has no projected approval timeline. This is categorically different from investigational compounds like retatrutide or orforglipron, which are in active Phase 3 programs with defined timelines and commercial sponsors. 5-Amino-1MQ remains a preclinical research compound.

For a compound to progress from its current status to FDA approval, it would need to complete IND-enabling studies (including formal toxicology and GMP manufacturing), a Phase 1 safety trial in humans, Phase 2 efficacy and dose-finding trials, and Phase 3 confirmatory trials — a process that typically takes 8 to 15 years and costs hundreds of millions of dollars with no guarantee of success. No pharmaceutical company has publicly announced a clinical program for 5-Amino-1MQ as of April 2026.

Academic interest in NNMT inhibition as a drug target is genuine. The 2021 review by Gao, Martin, and van Haren in Drug Discovery Today described NNMT as an emerging therapeutic target with increasing industry relevance. Whether that interest leads to a formal clinical program for 5-Amino-1MQ specifically — rather than for next-generation NNMT inhibitors developed by pharmaceutical companies — is unknown.

Understanding Your Metabolic Baseline

The biological pathways that 5-Amino-1MQ targets — adipose tissue metabolism, insulin signaling, glucose tolerance, SAM-dependent methylation, and NAD+ biology — are not abstract research constructs. They produce measurable signals in standard bloodwork. Whether or not a pharmacological NNMT inhibitor ever becomes available, the metabolic markers the NNMT axis influences are already quantifiable and clinically meaningful.

Fasting glucose, fasting insulin, and hemoglobin A1c reflect glycemic regulation and insulin sensitivity — the same endpoints improved in NNMT-inhibitor mouse studies. A comprehensive lipid panel characterizes the dyslipidemia pattern associated with central adiposity. ALT and AST track hepatic metabolism — now relevant given emerging NNMT literature in non-alcoholic fatty liver disease from Zhang, Zhu, Sun, and colleagues in Archives of Biochemistry and Biophysics in 2025. Body composition data (lean mass versus fat mass) contextualizes metabolic risk beyond BMI alone. For those interested in the methylation axis, homocysteine serves as a surrogate for SAM/SAH balance. These markers do not require waiting for a clinical trial. They are testable now.

That principle — understand your biology first, then make decisions with a provider — is central to Superpower's approach to preventive health. The compounds will change. The value of knowing your metabolic baseline will not.

IMPORTANT SAFETY INFORMATION

5-Amino-1MQ is NOT FDA-approved for any indication. No IND application has been publicly filed and no human clinical trials have been completed or published as of April 2026. Superpower Health does not prescribe, sell, compound, or facilitate access to 5-Amino-1MQ. This content is for educational purposes only.

No formal contraindications derived from human data exist because human safety trials have not been conducted. Use in humans is experimental. Based on mechanism and absence of human data, populations of particular concern include: pregnant or breastfeeding individuals; individuals with known or suspected malignancy; individuals taking medications affecting methylation pathways, folate metabolism, or SAM-dependent enzymes; individuals with hepatic or renal impairment.

Warnings: The human safety profile of 5-Amino-1MQ is unknown. Theoretical concerns include off-target effects of SAM elevation on cellular methylation broadly; effects on 1-methylnicotinamide-dependent signaling in skeletal muscle; unknown drug interactions; unknown long-term effects on cancer biology; unknown reproductive and developmental toxicology. Gray-market formulations are not manufactured under pharmaceutical GMP standards and have not been tested for purity, dosing accuracy, or contamination by a regulatory authority.

Common side effects: Not established. No human safety or tolerability data has been published.

Long-term safety data: Does not exist. All safety-relevant information comes from rodent studies not designed as formal toxicological evaluations.

WADA status: As of the 2026 WADA Prohibited List, 5-Amino-1MQ is not specifically listed; however, as a metabolic modulator, it may fall under the S4 Hormone and Metabolic Modulators category. Athletes subject to anti-doping rules should consult with their governing body before considering any investigational compound.

For NNMT inhibitor research context, see the ClinicalTrials.gov registry. No FDA-approved prescribing information exists for this compound.

Additional Questions

What is the difference between 5-Amino-1MQ and NR or NMN?

NR and NMN are NAD+ precursors that increase cellular NAD+ levels by supplying additional substrate for the salvage pathway. 5-Amino-1MQ inhibits NNMT, the enzyme that diverts nicotinamide away from NAD+ synthesis while also depleting SAM. In principle, the compounds work on adjacent but distinct nodes of the same pathway; 5-Amino-1MQ also addresses the methylation axis that NR and NMN do not. In practice, only NR has completed human RCTs, and evidence for meaningful metabolic benefit in humans is modest. 5-Amino-1MQ has no human data at all.

Can I get 5-Amino-1MQ from a compounding pharmacy?

Not through a legitimately operating 503A pharmacy following established clinical protocols. 5-Amino-1MQ is not on the FDA's list of bulk drug substances nominated for use in compounding, has no established safety or efficacy profile in humans, and has no prescribing indication. Gray-market vendors sell it as a research chemical; those products are not manufactured under pharmaceutical GMP standards and are not subject to regulatory oversight.

What are the risks of using 5-Amino-1MQ?

The human risk profile is unknown because no human safety studies have been conducted. Theoretical concerns include off-target effects of sustained SAM elevation on methylation biology, effects on 1-methylnicotinamide signaling in skeletal muscle, and unknown drug interactions. Long-term effects — including any implications for cancer biology, given NNMT's expression in tumor cells — have not been characterized. Gray-market products carry additional risks related to undetermined purity, dose accuracy, and contamination.

When might 5-Amino-1MQ become available as a prescription medication?

There is no established timeline. As of April 2026, no pharmaceutical company has publicly announced a clinical development program for 5-Amino-1MQ. Moving from preclinical status to FDA approval requires IND-enabling toxicology studies, Phase 1 through Phase 3 trials, and an NDA — a process of at minimum 8 to 15 years even under favorable conditions. There is no guarantee the compound will enter human trials.